Previous Article | Next Article ![]()
Infection and Immunity, June 2001, p. 3954-3964, Vol. 69, No. 6
Department of Microbiology and
Immunology1 and Department of
Pathology,2 Uniformed Services University of the
Health Sciences, Bethesda, Maryland 20814-4799, and Children's
Research Institute, Children's Hospital,3
and Division of Molecular Medicine, Department of Pediatrics,
College of Medicine and Public Health, The Ohio State
University,4 Columbus, Ohio 43205-2696
Received 3 January 2001/Returned for modification 9 February
2001/Accepted 12 March 2001
Cytotoxic necrotizing factor type 1 (CNF1) is a 115-kDa toxin that
activates Rho GTPases and is produced by uropathogenic Escherichia coli (UPEC). While both epidemiological
studies that link CNF1 production by E. coli with
urinary tract disease and the cytopathic effects of CNF1 on cultured
urinary tract cells are suggestive of a role for the toxin as a UPEC
virulence factor, few in vivo studies to test this possibility have
been reported. Therefore, in this investigation, we evaluated the
importance of CNF1 in a murine model of urinary tract infection (UTI)
by comparing the degree of colonization and damage induced by three different CNF1-producing E. coli strains with isogenic
CNF1-deficient derivatives. The data from single-strain challenge
experiments with C3H/HeOuJ mice indicated a trend toward higher counts
of the wild-type strains in the urine and bladders of these animals up
to 3 days after challenge in two of three strain pairs. Furthermore, this difference was statistically significant at day 2 of infection with one strain pair, C189 and C189cnf1. To
control for the animal-to-animal variability inherent in this model, we
infected C3H/HeOuJ mice with a mixture of CNF1-positive and -negative
isogenic derivatives of CP9. The CNF1-positive strain was recovered in
higher numbers than the CNF1-negative strain in the urine, bladders,
and kidneys of the mice up to 9 days postinfection. These striking
coinfection findings, taken with the trends observed in single-strain
infections, led us to conclude that CNF1-negative strains were
generally attenuated compared to the wild type in the C3H/HeOuJ mouse
model of UTI. Furthermore, histopathological examination of bladder
specimens from mice infected with CNF1-positive strains consistently
showed deeper, more extensive inflammation than in those infected with the isogenic mutants. Lastly, we found that CNF1-positive strain CP9
was better able to resist killing by fresh human neutrophils than were
CP9cnf1 bacteria. From these data in
aggregate, we propose that CNF1 production increases the capacity of
UPEC strains to resist killing by neutrophils, which in turn permits
these bacteria to gain access to deeper tissue and persist better in
the lower urinary tract.
Acute infections of the bladder and
kidneys in otherwise healthy individuals are among the most common
types of bacterial infections in humans (20, 44). Indeed,
there are an estimated 7 million episodes of acute cystitis and 250,000 cases of pyelonephritis in the United States every year (21,
39). This high incidence of disease disproportionately affects
women, about 40% of whom experience cystitis in their lifetimes.
Treatment of cystitis in women has been estimated to cost one billion
dollars annually (44).
Escherichia coli is the most frequently isolated bacterial
cause of uncomplicated urinary tract infection (UTI). Uropathogenic E. coli (UPEC) produces a number of virulence-associated
factors that include P fimbriae, hemolysin, aerobactin, and cytotoxic necrotizing factor type 1 (CNF1) (29). CNF1 is a
chromosomally encoded UPEC toxin that catalyzes the deamidation of the
small GTPases RhoA, Rac, and Cdc42 (12, 14, 30, 42).
Deamidation by CNF1 renders these GTPases constitutively active, which
in most cells leads to the formation of actin stress fibers,
lamellipodia, and filopodia. HEp-2 cells, which have been used as the
prototypic cells for evaluation of CNF1 toxicity, not only display
actin stress fibers but also become multinucleated (6, 10,
40). Additionally, CNF1 has been reported to (i) induce
phagocytosis in epithelial cells (9, 11), (ii) reduce
CR3-dependent phagocytosis in monocytes (5), (iii)
increase the permeability of Caco-2 intestinal cell monolayers
(14), (iv) efface the brush border of and decrease the
transmigration of polymorphonuclear leukocytes (PMN) across a T84
monolayer (18), (v) inhibit wound repair in T24 bladder
cells and Hs 738 fibroblast cells (24), and (vi) kill 5637 bladder cells through an apoptotic mechanism (34). Thus,
CNF1 affects a variety of cellular functions in vitro, presumably through activation of the Rho GTPases. However, the role of this toxin
in the pathogenesis of UTI remains to be delineated.
Several groups have reported an epidemiological link between the
presence of the cnf1+
genotype or the production of CNF1 and E. coli strains that
cause extraintestinal disease. Indeed, Yamamoto et al. showed that 61% of UTI isolates and 38% of bacteremia isolates harbored the
cnf1+ gene, as opposed to
only 10% of commensal fecal isolates (45). Furthermore,
Mitsumori et al. reported that 64% of prostatitis isolates and 36% of
pyelonephritis isolates were
cnf1+ (35)
and Andreu and colleagues reported that the percentages of
cnf1+ prostatitis, pyelonephritis, and
cystitis isolates were 63, 48, and 44%, respectively (3).
Caprioli et al. found that 40% of UTI isolates tested positive for
CNF1 expression, while only 0.9% of fecal isolates produced CNF1
(6). The common finding of
cnf1+ in E. coli strains that cause extraintestinal infections is also consistent with the strong correlation between the presence of cnf1+ and the gene for
hemolysin, hly, in these isolates. In fact, Yamamoto et al.
reported that approximately 76% of isolates of E. coli from
extraintestinal sites that were hly+ were
also cnf1+, while 98% of
cnf1+ strains were also
hly+ (45).
In this study, we used a mouse model of ascending UTI to evaluate the
role that CNF1 may play in the pathogenesis of UTI. We found that in
two of three CNF1-positive UPEC strains tested, the bacterial counts in
the bladders and urine of mice early in infection were higher than in
those of animals inoculated with the respective isogenic
cnf1 deletion mutant. In a few
single-strain studies and in all mixed-inoculum studies, this
difference was statistically significant. We also showed that CNF1 may
alter the host response to infection, therefore allowing the bacteria to penetrate deeper into the muscular wall of the bladder and cause
more severe and prolonged infection.
Bacterial strains, plasmids, media, and growth conditions.
The bacterial strains and plasmids used in this study are listed in
Table 1. The media used were Luria
Bertani (LB) broth, LB agar, and MacConkey agar (Difco,
Becton-Dickinson, Sparks, Md.). When appropriate, ampicillin was used
at 100 µg/ml of medium. Chloramphenicol was used at 30 µg/ml where
necessary. Bacteria were routinely grown at 37°C.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3954-3964.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Mutation of the Gene Encoding Cytotoxic Necrotizing
Factor Type 1 (cnf1) Attenuates the
Virulence of Uropathogenic Escherichia
coli
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Bacterial strains and plasmids used in this study
Cloning of
cnf1+.
Commercially synthesized primers (Life Technologies, Inc.,
Gaithersburg, Md.) were designed to amplify
cnf1+ from E. coli strain J96 (23) by PCR. The sequences of the
primers were as follows: forward,
5'-TATTAATCTTCACAGAGGAG-3'; reverse, 5'-GGCCAATAAATAATTTCCCGAATC-3' (8).
Amplification reaction mixtures contained 1× PCR buffer (Perkin-Elmer,
Foster City, Calif.), 0.2 mM each deoxynucleoside triphosphate
(Perkin-Elmer), 1.0 µM each primer, 1.5 mM
MgCl2, 10 to 20 ng of template DNA, and 2.5 U of
Taq polymerase (Perkin-Elmer). Reaction mixtures were
incubated in a thermocycler for 30 consecutive cycles of 1 min at
95°C, 1 min at 50°C, and 3 min at 72°C with a final extension at
72°C for 10 min. The PCR amplification product was purified (Wizard DNA Purification Kit; Promega Corp., Madison, Wis.) from
low-melting-point agarose (SeaPlaque; BioWhittaker Molecular
Applications, Rockland, Maine) and cloned in the SmaI site
of pBluescript II SK(
) (Stratagene Cloning Systems, La Jolla,
Calif.). The cnf1+ plasmid
clone pHLK102 (Table 1) expressed CNF1 biological activity in the
HEp-2 multinucleation assay and contained the restriction enzyme
recognition sites predicted from the published
cnf1+ DNA sequence
(8).
) (Stratagene Cloning Systems) to generate pHLK116. The
cnf1+ fragment was
reisolated following digestion of pHLK116 with SacI and
SalI and subcloned into pSX34lacZ
(obtained
from S.-Y. Xu, New England Biolabs, Beverly, Mass.) to produce pHLK140
(Table 1).
Construction of cnf1 isogenic
mutants.
An in-frame deletion mutation (pHLK120) was constructed
by the removal of an internal 1.2-kb BclI
cnf1+ fragment from
pHLK102. The mutation (
cnf-120) produced a truncated CNF1
protein that was detectable with CNF1-specific polyclonal antiserum
(34), but strains carrying the
cnf-120
mutation expressed no detectable CNF1 biological activity. A 2.0-kb
BssHII fragment from pHLK120 that contained the
cnf-120 mutation was ligated into the BssHII
site in the suicide vector pAM450 (31) to yield pHLK125,
which was subsequently used as previously described (16, 31) to introduce the
cnf-120 mutation into
different UPEC strains. For allelic exchange, bacteria were transformed
with pHLK125 under selection for ampicillin resistance
(Ampr) at 30°C. Transformants then underwent
selection for Ampr at 42°C to isolate
cointegrates that were subsequently plated at 30°C on LB agar without
added NaCl and containing 5% sucrose to allow resolution of the
plasmid. The resulting isogenic mutants were screened for loss of
plasmid markers and loss of CNF1 activity. The replacement of the
wild-type cnf1 gene with the
cnf-120 allele was confirmed by PCR, Southern blot, and
Western blot analyses. E. coli strains that carried the
cnf-120 mutation were complemented in vitro with the
wild-type cnf1 gene in pHLK102 or pHLK140
(Table 1). Growth curves of the wild-type and mutant strains were done in minimal-salts liquid containing glucose and in L broth over a 24-h
period. The growth rates of the strain pairs appeared
indistinguishable. Moreover, the plating efficiencies of the mutants on
L agar and MacConkey agar were indistinguishable from those of the
parental strains. All strains were tested for retention of the O
antigen, capsular antigen (where present), type 1 pili, P fimbriae,
hemolysin, and lipopolysaccharide by standard procedures.
Isolation of CP9lacZ.
Standard methods
(32) were used to isolate and characterize a
Lac
derivative of E. coli strain
CP9, designated CP9lacZ (Table 1). Phenotypic and
complementation analyses of CP9lacZ localized the mutation
to lacZ, and the mutant was otherwise indistinguishable from
strain CP9 in vitro or in vivo.
HEp-2 multinucleation assays. Ninety-six-well tissue culture plates were seeded with 4 × 103 HEp-2 cells per well and incubated for 4 h at 37°C with 5% CO2. Overnight bacterial cultures were harvested by centrifugation, concentrated by resuspension in phosphate-buffered saline plus gentamicin (100 µg/ml), and disrupted by sonication. The resultant lysates were clarified by centrifugation at 4°C and sterilized by filtration. Serial dilutions of the lysates were applied to the HEp-2-seeded wells, and the microtiter plates were further incubated for 72 h before the wells were fixed and stained with Leukostat (Fisher Scientific, Pittsburgh, Pa.). Multinucleation of HEp-2 cells was assessed by microscopy.
Mouse UTI model.
Animal experiments were carried out in
accordance with the principles outlined in the Guide for the Care
and Use of Laboratory Animals (38). The mouse
ascending UTI model was performed as previously described (15,
28, 36, 37). All of the E. coli strains evaluated in
this model were first passed through mice as described below to ensure
that the strains were not attenuated as a result of routine laboratory
culture. The bacteria were isolated from infected kidneys at 2 to 5 days postinfection and stored at
70°C. The strains did not lose any
virulence factors or CNF1 expression due to animal passage. To prepare
inocula for mice, mouse-passaged bacteria were harvested from an LB
agar plate after overnight incubation and resuspended in sterile,
nonpyrogenic saline to an A600 of
1.12. Six milliliters of the bacterial suspension was pelleted and
resuspended in 0.5 ml of saline to give a bacterial density of
109 CFU/ml. This suspension was adjusted by
dilution so that 1 × 107 to
1 × 108 CFU were
contained in 10 or 25 µl. The inoculum was pipetted into an adapter
tube (6-in. Male/Female line; Surgimedics, The Woodlands, Tex.)
connected to a 30-gauge, 0.5-in. sterile needle. The pipette tip was
left in the tubing, and an electronic EDP pipettor (Rainin Instrument
Co., Woburn, Mass.) was attached to the tip.
Histopathology. Organs were soaked in 10% phosphate-buffered formalin for a minimum of 4 h, embedded in paraffin, and cut into 5-µm sections. The slides were stained with hematoxylin and eosin and examined for depth of inflammation. Bladder sections were also stained with Brown-Brenn stain for bacteria. Sections were coded and viewed in a blinded fashion under ×600 magnification, and the area of greatest inflammation was located. Neutrophils and band forms were counted in that area. Severity of inflammation was scored according to the following scale: 0 to 25 neutrophils present, mild inflammation; 26 to 50 neutrophils present, moderate inflammation; greater than 50 neutrophils present, severe inflammation. No neutrophils were observed in saline-inoculated control animal sections.
Neutrophil killing of bacteria in vitro Overnight cultures of bacteria were washed and suspended in Hanks' balanced salt solution containing gelatin (1.0 mg/ml). Fresh human neutrophils were isolated from whole venous blood and suspended in Hanks' balanced salt solution-1.0 mg of gelatin per ml (4). Bacteria and neutrophils were mixed at ratios of two to five bacteria per neutrophil and incubated at 37°C with gentle tumbling. After 15 and 45 min of incubation, samples were plated on LB agar. The percentage of viable bacteria after incubation with neutrophils was calculated according to the following formula: % viable bacteria = (number of bacterial CFU in the mixtures at 15 or 45 min/number of bacterial CFU added to the mixtures at the start of the assay) × 100.
Statistical analysis. The geometric mean number of CFU of bacteria from the urine, bladders, or kidneys of a group of mice infected with the wild-type strain was compared to the geometric mean number of CFU in mice infected with the mutant strain by using unpaired Student t tests. When the geometric mean numbers of CFU of a group of strains were compared, as in Fig. 1, an analysis of variance was used to evaluate the variance, followed by unpaired Student t tests to compare the means of two strains. The numbers of CFU from mice coinfected with two strains were compared by Student t tests of paired log10 numbers. A Student t test of paired samples was also used to examine the data obtained from the neutrophil-killing experiments.
| |
RESULTS |
|---|
|
|
|---|
Rationale for selection of E. coli strains for mouse
UTI studies.
Experiments were initially undertaken in the mouse
UTI model with the well-characterized O4:H5:K6 UPEC strain J96.
However, we concluded, on the basis of a set of experiments in which we varied a number of parameters to optimize the model, that the colonization levels of J96 were invariably too low to allow us to
discern a difference between the wild-type and mutant
J96cnf1 strains. Therefore, we sought to
find CNF1-expressing UPEC strains that were more virulent (i.e.,
colonized the bladder and/or kidneys at higher levels) than J96 in the
mouse model. For that purpose, we compared J96 with three independent
CNF1-producing clinical isolates, CP9, C85, and C189 (Table 1)
(41, 45). Colonization levels in the urine, bladder, and
kidneys were significantly higher than those of J96 for all three
strains (P < 0.05) except for C189 in the bladder
(Fig. 1). Therefore, we proceeded to
prepare isogenic cnf1 mutants of these
strains (designated CP9cnf1,
C85cnf1, and
C189cnf1) by allelic exchange as we had
done for J96. We then selected one strain pair, CP9 and
CP9cnf1, to use in a series of studies in
the mouse UTI model to assess the impact on relative bacterial counts
of the time when samples were harvested after infection (kinetics of
infection), the strain of mouse used as the host animal, and the
challenge dose. When we evaluated the importance of these variables in
the pairwise comparison, we also, on occasion, tested other
CNF1-positive and CNF1-negative pairs.
|
Kinetics of infection of C3H/HeOuJ mice with CP9 and
CP9cnf1 in the UTI model.
The goal of
our first set of experiments with CP9 and
CP9cnf1 was to define the optimal time for
harvesting of infected urine, bladders, and kidneys for comparative
enumeration. For this purpose, 30 mice per strain were inoculated with
1.9 × 107 CFU and 10 mice per strain were
euthanatized at 1, 3, and 5 days postchallenge. At day 1 after
inoculation, urine and bladder samples collected from mice infected
with CP9 contained higher numbers of bacteria than did samples
collected from CP9cnf1-infected mice (Fig.
2A). However, at day 3 postinfection,
bacterial counts in the urine, bladders, and kidneys of mice infected
with either strain were equivalent, although the absolute numbers for
each type of sample were higher for both strains than on day 1 of
infection (Fig. 2B). By 5 days after infection, mice challenged with
CP9 again had somewhat higher bacterial numbers in their urine than did
mice given CP9cnf1 but the bacterial
numbers in the bladder slightly favored the mutant while equal numbers
of bacteria of both strains were present in the kidney samples (Fig.
2C). Although none of the observed differences were statistically
significant, the trend toward higher numbers of CNF1-positive bacteria
in the urine and bladder on the first day following inoculation led us to focus on colonization in the first days of infection.
|
Comparison of CP9 and CP9cnf1 early in
infection of C3H/HeOuJ or BALB/c mice in the UTI model and influence of
challenge dose on infection of C3H/HeOuJ mice.
For the next series
of kinetic studies, we again compared our prototypic strains, CP9 and
CP9cnf1, but focused only on days 1 to 3 of
infection. We also compared the influence of the mouse strain on the
outcome at day 1 postchallenge. As with the previous kinetic
experiments, 1 day after infection, C3H/HeOuJ mice challenged with
strain CP9 had higher bacterial numbers in their urine and bladders
than did mice challenged with the mutant (Fig.
3A). When identical experiments were done
with BALB/c mice (Fig. 3B), the bladder samples had slightly higher
numbers of wild-type CP9 bacteria while slightly higher numbers of
CNF1-negative bacteria were present in the urine and kidney samples.
Two days after infection, urine samples of C3H/HeOuJ mice infected with
CP9 contained slightly more bacteria than did samples from
CP9cnf1-infected mice (Fig. 3C). Bladders
and kidneys were infected equally with the wild-type and mutant
strains. BALB/c mice were not tested at this time point. From these
data, we concluded that day 1 after challenge of C3H/HeOuJ permitted
the best discrimination between the CNF1-postive CP9 strain and its
isogenic mutant and that BALB/c mice did not display this difference
across all sample types. Therefore, we elected to use C3H/HeOuJ mice in
the remaining studies.
|
2 × 107 bacteria as our challenge inoculum. In these
experiments, we asked whether, if we raised the dose of the inoculum,
we could discern a difference between the counts of CP9 and its
isogenic mutant later in infection than day 1. We found that when we
elevated the challenge inoculum to 108 bacteria,
the answer was yes, at least for the urine and bladder samples (Fig.
3D). Thus, in this higher challenge dose experiment, significantly more
CP9 than CP9cnf1 bacteria were present in
the urine and bladder samples (P < 0.05) at day 3 of
infection. The kidneys were colonized equally by both strains.
Evaluation of additional CNF1-postive and CNF1-negative isogenic
pairs of UPEC strains early in the infection of C3H/HeOuJ mice in the
UTI model.
To determine whether our findings obtained with the CP9
and CP9cnf1 pair could be reproduced with
other such pairs, we did comparative analyses of the numbers of C85 and
C189 bacteria with those of their respective isogenic mutants at days 1 and 2 postinoculation. We found that the importance of CNF1 to the
colonization levels of C85 and C189 differed. At 1 day postinoculation,
C3H/HeOuJ mice infected with 1.9 × 107 C85
or C85cnf1 bacteria had equivalent numbers
of CFU in the kidneys whereas the numbers of wild-type bacteria in the
urine and bladders were slightly lower than those of mutant bacteria (data not shown). In contrast, when mice that were inoculated with
1.0 × 108 CFU of strains C189 and
C189cnf1 were examined at 2 days
postchallenge (day 1 was not tested), statistically significantly
higher numbers of wild-type bacteria were found in the urine and
bladders (Fig. 4). Colonization of the
kidneys showed a trend toward higher numbers of C189 than
C189cnf1 bacteria, but this trend was not
statistically significant.
|
Mixed-strain infections.
The mixed-infection model allows
direct comparison of two strains in a single animal and eliminates the
variation between animals that is inherent in the single-infection
model system. Therefore, a Lac-negative derivative of CP9 was
generated by UV irradiation for use in such an experiment.
This CNF1-producing strain, designated CP9lacZ, could be
differentiated from Lac-positive CP9cnf1 on
MacConkey agar. To confirm that generation of the
Lac
phenotype did not alter the virulence of
CP9lacZ, that strain was tested against the parental strain
in a mixed infection. The two strains were mixed in a 1:1 ratio and
used to inoculate C3H/HeOuJ mice intravesically (Fig.
5A). Urine and kidney samples from mice euthanatized 2 days postinoculation contained equal numbers of each
strain. Slightly higher numbers of wild-type CP9 bacteria were found in
the bladders, but the difference in the numbers of each strain was not
significant. Based on these data, it was determined that
CP9lacZ could infect mice as well as CP9. CP9lacZ was then tested against CP9cnf1 in the
mixed-infection model. The strains were mixed in equal numbers and used
at an inoculum of 108 CFU per strain, a dose
similar to that previously shown to discriminate well between CP9 and
CP9cnf1 in single-dose experiments at 3 days postinfection (Fig. 3C). This mixture was used to infect C3H/HeOuJ mice (Fig. 5B). Two days postinfection, CNF1-positive
CP9lacZ had grown to significantly higher numbers than
CP9cnf1 in the urine, bladders, and kidneys
of the mice tested (P < 0.05; Fig. 5B). Next, a time
course study was done with the same mixture of CP9lacZ and
CP9cnf1 as in the previous experiment. Mice
were infected intravesically with the mixture and sacrificed 6 h,
2 days, 4 days, 7 days, and 9 days postinoculation (Fig.
6). In the urine, the numbers of CFU of
both strains increased between 6 h and 2 days. Between 2 and 9 days, the number of CFU of each strain decreased but the decrease
in the number of CP9cnf1 bacteria was more
rapid than the decrease in the number of CP9lacZ bacteria (Fig. 6A). In the bladder, the number of CFU of CP9lacZ
bacteria was stable throughout the experiment while the number of
CP9cnf1 CFU decreased (Fig. 6B).
CP9cnf1 and CP9lacZ numbers
decreased in the kidneys during the 9-day period, with the average
number of CP9lacZ CFU decreasing by 1.5 log units (Fig. 6C).
In contrast, CP9cnf1 was nearly cleared
from the kidneys after 9 days. The average numbers of CFU of the
cnf1 isogenic mutant decreased by 5.8 log
units (Fig. 6C), and in 100% (six of six) of the infected kidneys,
bacteria were only detectable after enrichment culture. Results of the
mixed-infection time course study indicate that the wild-type strain
consistently colonized the mice at higher levels than did the
cnf1 isogenic mutant strain. In addition, there was more rapid clearing of the mutant strain from the urinary tracts of the mice.
|
|
Complementation of CP9cnf1 with a cloned
cnf1+ gene.
The
results obtained with the mixed-infection model indicated higher
colonization of the urinary tract by the wild-type strain. To confirm
our assumption that the defect of CP9cnf1
was, in fact, a consequence of the absence of CNF1 expression, we
attempted in vivo complementation studies. The
cnf1+ gene was cloned from
cosmid 2CO2 into pSX34lacZ
, a low-copy-number vector
derived from pSC101. The resulting construct, designated pHLK140, was
transformed into CP9cnf1 and expressed CNF1
at a level that was five times higher than wild-type expression in CP9.
However, we found that pHLK140 was not stable in vitro, either in the
presence or in the absence of antibiotic selection, perhaps due to the
toxicity of overexpressed CNF1. When tested in the mouse model, the
vector alone was stable in the absence of antibiotic selection. Similar
to our findings with in vitro passage of transformants harboring
pHLK140, this plasmid was not completely stable in vivo in the
absence of selection. Loss of the plasmid was detected in the urine and
kidney samples but not in the bladder samples. In mixed complementation
infection experiments with
CP9lacZ(pSX34lacZ
) (Lac negative, CNF1
positive, vector only) and CP9cnf1(pHLK140) (Lac positive, CNF1 positive), there were no differences in the numbers
of bacterial CFU recovered from the bladders. pHLK140 was retained by
83% of CP9cnf1 in the urine and 73% of
CP9cnf1 in the kidneys, and half as many of
these bacteria were recovered from either site as were CNF1-positive
CP9lacZ(pSX34lacZ
) bacteria. Thus,
functional complementation appears to have occurred in the bladders,
indicating some selective pressure for retention of the plasmid in the
bladders, but not in the urine or kidneys, of the mice. We cannot
preclude the possibility that overexpression of CNF1 in the kidneys
impaired the survival of the mutant at that site. These results, taken
together with the results of the single- and mixed-infection
experiments, indicate that production of CNF1 allows better infection
of the bladder by UPEC.
Histological analysis of bladder samples and light microscopic
examination of urine from infected mice.
Single and mixed
infections, as well as complementation experiments, showed that in the
mouse model of UTI, CNF1 conferred an advantage on CP9 in the bladder.
Therefore, we focused our histological evaluations on formalin-fixed
bladder tissue from mice infected with that strain or
CP9cnf1. Microscopic examination of
infected bladder sections stained with hematoxylin and eosin revealed
that both wild-type and mutant strains elicited an acute inflammatory
response from the host that consisted of an influx of neutrophils and
edema. The location of the influx of neutrophils ranged from the
epithelium only in some bladders through the muscularis in others. The
percentage of bladders infected with CP9 that exhibited moderate-to-severe inflammation (Table 2)
was higher than in the CP9cnf1-infected
bladders (100% versus 20%). These comparative data from isogenic
strains that differ only in CNF1 production suggest that inflammation
of the submucosa and muscularis may be more severe in the bladders of
animals infected with CNF1-positive bacteria. In support of this
premise, bacteria were visible (by Brown-Brenn staining) within the
areas of inflammation (data not shown).
|
Killing of bacteria by neutrophils. The finding of increased inflammation within the bladder tissue of wild-type-infected mice compared to mutant-infected animals prompted us to examine the interaction of neutrophils with the bacteria. We examined the ability of freshly isolated human neutrophils to kill CP9 and CP9cnf1 after incubation of the bacteria and neutrophils together for 15 and 45 min. Despite day-to-day variation in neutrophil viability and bactericidal activity, isolated neutrophils were less effective in killing wild-type CP9 than in killing CP9cnf1 (data not shown). In seven of eight samples, the viability of CP9 after 15 or 45 min of exposure to neutrophils was significantly greater than that of CP9cnf1 (P < 0.05). Lysates prepared from the CP9-neutrophil mixture after incubation expressed CNF1, as demonstrated by the multinucleation of HEp-2 cells. This activity was not present in the CP9cnf1-neutrophil incubation mixture. These data indicated that human neutrophils kill CNF1-negative UPEC more effectively than they kill isogenic CNF1-positive UPEC.
| |
DISCUSSION |
|---|
|
|
|---|
In this investigation, we sought to test the hypothesis that CNF1 contributes to the virulence of UPEC through the use of a mouse model of ascending UTI. Prior to this report, the evidence in favor of such a proposal was primarily based on epidemiological findings (3, 6, 35, 45) and, more indirectly, the cytopathic effects of CNF1 on a human bladder epithelial cell line, 5637 (34). The evidence against such a theory was recently presented by Johnson and colleagues (26). Those investigators used the same general approach that we employed in our investigation: a comparison of the net growth and histological damage induced by a CNF1-positive UPEC strain to those of its isogenic cnf1 mutant in a mouse model of ascending UTI. Although we do not dispute the conclusions of those researchers that CNF1 did not contribute to the virulence of the UPEC strain that they tested, our results, for the reasons described below, led us to the opposite conclusion. Indeed, we generated four lines of evidence to support our original tenet. First, in single-challenge inoculation experiments, we showed that up to 3 days after single-strain intravesical challenge, two of the three CNF1-producing strains tested achieved greater numbers in the urine and bladders of mice than did their respective cnf1 isogenic mutants. On days 1, 2, and 3 after challenge, the average numbers of CFU of CP9 were higher than the average numbers of CFU of CP9cnf1 in the urine or bladders. Strain C85 was only tested at day 1, and it was present in slightly lower numbers in the urine and bladders than its cnf1 isogenic mutant at that point of infection. C189 and its isogenic mutant were tested only on day 2 of infection, and at that time, the wild-type strain was present in higher numbers in the urine and bladders than C189cnf1. Second, in mixed-inoculation studies, CP9 consistently outgrew CP9cnf1 in the urine and tissues of the urinary tract. Third, CNF1-positive strains CP9 and C85 induced a greater degree of inflammation and appeared to traverse deeper into the bladder tissue at day 1 of infection than did CP9cnf1 and C85cnf1, respectively, even though the latter strain was present at slightly higher numbers than its wild-type parent. Fourth, CP9 survived better in the presence of human neutrophils than did CP9cnf1.
That the conclusions of this study and the report of Johnson et al. (13, 26) are contradictory may be explained, in part, on the basis of differences in certain experimental variables used by the two groups. The parameters that are known to alter the severity and time course of single-strain challenge studies in the mouse UTI model include the following. First, the type of human isolate influences the infection, i.e., strains from a patient with cystitis or pyelonephritis (reference 27 and Fig. 1 of this study). Indeed, Johnson and colleagues previously reported that cystitis isolates colonize the mouse bladder and urine better than do pyelonephritis isolates whereas pyelonephritis isolates colonize the kidneys at higher levels. The strain used by Johnson et al. for their analysis of the contribution of CNF1 to the urovirulence of E. coli in the mouse model was F11, an isolate from the urine of a patient with symptoms of cystitis (26). In our experiments, we primarily examined CP9, a strain isolated from the blood of a patient (41). We also tested C85 and C189, both of which are cystitis isolates. Second, the strain of mouse used in the model may also affect the pattern of infection, as demonstrated by Hopkins et al. (22). Those investigators examined the time course and host response of various mouse strains to a single E. coli strain and concluded that mice of various strains differ in their initial susceptibility to infection and in the ability to resolve an infection. In our studies, infection of BALB/c mice with CP9 and CP9cnf1 resulted in higher numbers of the mutant strain in the urine and kidneys of the mice (but not the bladder) at 1 day of infection. Conversely, when C3H/HeOuJ mice were infected with the same dose and the same strains, there were higher numbers of the wild-type strain than the mutant in the urine and bladders of the mice on that first day of infection. In addition, the overall numbers of bacteria in the urine and tissues of C3H/HeOuJ mice were higher than the numbers in the comparable specimens from BALB/c mice. These differences could indicate that for the BALB/c infections, the time of sampling was not optimal for observation of an effect of CNF1 on the infection process. In contrast, the data could also indicate that CNF1 does not play a role in the infection of BALB/c mice. Since Johnson et al. used CBA/J/Hsd mice (26), perhaps the absence of a demonstrable effect of CNF1 on the urovirulence of F11 could reflect their choice of mouse strains for these experiments. Third, the time in infection at which the comparison between a CNF1-positive and a CNF1-negative strain was made had an impact in our studies of mice that were inoculated with single bacterial strains (earlier was generally better at a comparable dose). We focused our single-strain infection experiments on days 1 to 3; Johnson et al. focused most of their experiments on a 7-day infection period. Fourth, the challenge dose might have an impact on the outcome of a differential analysis between the wild type and an isogenic cnf1 mutant. We generally used an inoculum of 2 × 107 CFU per mouse in single-strain studies, while Johnson and colleagues used a dose of 2 × 109 CFU. The higher dose might obscure the type of trends that we observed between CNF1-postive and CNF1-negative isogenic mutants in single-strain inoculation experiments. Finally, the spectrum of additional virulence determinants expressed by a particular UPEC strain (e.g., hemolysin, cytolethal distending toxin) might alter or mask the influence that CNF1 has on the pathogenesis of infection. In fact, in our study, the only strain pair in which a statistically significant difference in colony counts (rather than a trend) was observed between the wild-type and mutant strains in single-strain infection studies was with the hemolysin-negative isolate C189.
Taken together, the general trends of our single-strain challenge studies with C3H/HeOuJ mice suggested that CNF1 contributed to UTI early in the infection process in the mouse model in two of the three strains tested. However, the variation in bacterial numbers in each animal test group made it difficult to draw definitive conclusions supported by statistically significant differences in the geometric mean numbers of CFU. This wide range of counts within experimental groups has been previously demonstrated (26, 37) and may reflect differences between individual animals' responses to infection. Some individual animals may clear the initial infection faster than others because of their immune system efficiency or the speed with which the animals urinate after infection. Regardless of the reason for the variability, when such variation among animals was minimal or experimentally controlled for by utilizing mixed infections (see below), there were statistically significant differences between the numbers of CFU of strains CP9 and CP9cnf1 recovered from the urine.
A mixed-infection model was utilized to control for the variation in severity of infection from animal to animal. To our knowledge, this is the first published study comparing a CNF1-positive strain to an isogenic CNF1-negative mutant in a mixed-infection model. We generated a Lac-negative mutant of strain CP9 (CP9lacZ) to differentiate the parent from the isogenic cnf1 mutant. When equal numbers of CP9lacZ and CP9cnf1 bacteria were inoculated into mice, CP9lacZ was recovered in significantly higher numbers from the urinary tract than CP9cnf1. The capacity of CP9lacZ to outgrow CP9cnf1 in the urinary tract was not due to a difference between the growth rates of the bacteria, as demonstrated in vitro. Rather, CNF1 appeared to confer an advantage on the bacterium in the urinary tract. In fact, time course studies of mixed infections showed that the CNF1-positive strain was able to persist in the bladder and kidneys whereas CP9cnf1 was cleared more rapidly from the urinary tract. In a previous report, Miller and Creaghe described mixed-infection studies with two unrelated E. coli strains isolated from a patient with pyelonephritis (33). When they inoculated a mixed culture directly into the kidney, they found stable cocolonization of the kidney, but when inoculation was by a retrograde infection, a serogroup O8 strain was found to infect the kidneys to the exclusion of a serogroup O75 strain. The investigators concluded that bacterial interference played some part in infection of the kidney by a single strain. The influence of virulence factors was not discussed in that report, but another explanation for these results may be that the O8 strain possessed virulence determinants that gave that strain an advantage over the other strain. Our experimental design differs from that of Miller and Creaghe in that we used isogenic strains isolated from blood that varied only in CNF1 production and lactose utilization. We concluded that the capacity of CP9lacZ to colonize the urinary tract in higher numbers than CP9cnf1 is due to the presence of CNF1.
We examined the basis for the apparent advantage that production of CNF1 conferred on UPEC strains in this model. Histological analysis of bladder samples taken from mice 1 day after infection indicated that CNF1-positive bacteria caused severe inflammation more often than the isogenic mutants (Table 2). Functional complementation of the cnf1 mutant also was evident in the bladder, a result consistent with a role for CNF1 in UPEC pathogenesis at that site. One possible benefit of CNF1 production by bacteria in bladder tissues is that the toxin induces epithelial cells to take up the bacteria and promote their transcytosis across the mucosal barrier. In fact, Falzano et al. reported that CNF1 induced phagocyte-like activity in human epithelial cells, allowing the uptake of noninvasive bacteria (9). Alternatively, cell death caused by CNF1 (34) or tissue damage due to a more intense inflammatory response to CNF1-positive strains may allow the infecting strain to gain access to deeper tissues. Infiltration of PMN was found more often in the mucosa and submucosa of bladders infected with CNF1-positive strains. Abnormal multinucleation was not evident in any of the bladder sections examined, a finding consistent with a recent report on the differences in the effects of CNF1 on human bladder 5637 cells (cytotoxicity) and HEp-2 cells (multinucleation) (34).
That CNF1 production may increase the inflammatory response of the host is suggested by our observations and the work of others. Specifically, Elliott et al. reported that CNF1 evokes edema and necrosis and is associated with inflammation in the intestines of rabbits in a diarrhea model of infection (7). Additionally, Fournout et al. found that germfree piglets infected orally with a CNF1-positive E. coli strain developed pulmonary inflammation more frequently than those infected with an isogenic CNF1-negative mutant (13). In that study, CNF1-positive and CNF1-negative bacteria were both disseminated in the lungs of the infected pigs. Hofman et al. recently reported that treatment of isolated PMN with purified CNF1 for 16 h, followed by stimulation with zymosan, resulted in an increase in superoxide generation and adherence of PMN to T84 cells; however, the phagocytic function of CNF1-treated PMN was decreased (19). Our observation that human neutrophils are less effective at killing CNF1-positive bacteria than CNF1-negative bacteria may result from decreased phagocytosis of the bacteria by the neutrophils.
If CNF1 gives bacteria an advantage in persistence in the lower urinary tract, how does that happen in the face of the host responses to bacterial entry into the bladder? The defensive responses of the host include the washout flow of urine, shedding of the uroepithelium, and production of an acute inflammatory response, with the resultant production of host cytokines, such as interleukins 6 and 8, that increase the influx of polymorphonuclear lymphocytes into the area (1, 2, 17). Our results show that CNF1 production protects UPEC from killing by neutrophils. That result should be viewed in the context of the fact that CNF1-producing bacteria have been reported to evoke greater granulocyte colony-stimulating factor levels in patients than E. coli strains that do not produce CNF1 (25). Granulocyte colony-stimulating factor plays a role in maintaining the normal blood neutrophil count and determining the neutrophilic response to infection in the human host. Thus, in spite of an apparent capacity of CNF1-positive bacteria to recruit neutrophils to the site of infection, the toxin acts to protect the bacteria from neutrophilic attack.
| |
ACKNOWLEDGMENTS |
|---|
This research was supported by National Institutes of Health grant AI38281-05.
We thank Raghav Wusirika for help with the neutrophil experiments and Rebecca Gillespie and Beth Baker for assistance with the animal experiments. We are also grateful to Karen Meysick for critical evaluation of the manuscript and many helpful suggestions.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Children's Research Institute, 700 Children's Dr., Columbus, OH 43205-2696. Phone: (614) 722-2646. Fax: (614) 722-3273. E-mail: LockmanH{at}pediatrics.ohio-state.edu.
Editor: J. T. Barbieri
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Agace, W., H. Connell, and C. Svanborg. 1996. Host resistance to urinary tract infections, p. 221-243. In H. L. T. Mobley, and J. W. Warren (ed.), Urinary tract infections: molecular pathogenesis and clinical management. American Society for Microbiology, Washington, D.C. |
| 2. | Agace, W., S. Hedges, M. Ceske, and C. Svanborg. 1993. IL-8 and the neutrophil response to mucosal gram negative infection. J. Clin. Investig. 92:780-785. |
| 3. | Andreu, A., A. E. Stapleton, C. Fennell, H. A. Lockman, M. Xercavins, F. Fernandez, and W. E. Stamm. 1997. Urovirulence determinants in Escherichia coli strains causing prostatitis. J. Infect. Dis. 176:464-469[Medline]. |
| 4. | Campbell, D. E., and S. D. Douglas. 1997. Phagocytic cell functions. I. Oxidation and chemotaxis, p. 320-328. In N. R. Rose, E. C. de Macario, J. D. Folds, H. C. Lane, and R. M. Nakamura (ed.), Manual of clinical laboratory immunology, 5th ed. ASM Press, Washington, D.C. |
| 5. |
Capo, C.,
S. Meconi,
M.-V. Sanguedolce,
N. Bardin,
G. Flatau,
P. Boquet, and J.-L. Mege.
1998.
Effect of cytotoxic necrotizing factor-1 on actin cytoskeleton in human monocytes: role in the regulation of integrin-dependent phagocytosis.
J. Immunol.
161:4301-4308 |
| 6. |
Caprioli, A.,
V. Falbo,
F. M. Ruggeri,
L. Baldassarri,
R. Bisicchia,
G. Ippolito,
E. Romoli, and G. Donelli.
1987.
Cytotoxic necrotizing factor production by hemolytic strains of Escherichia coli causing extraintestinal infections.
J. Clin. Microbiol.
25:146-149 |
| 7. |
Elliott, S. J.,
S. Srinivas,
M. J. Albert,
K. Alam,
R. M. Robins-Browne,
S. T. Gunzburg,
B. J. Mee, and B. J. Chang.
1998.
Characterization of the roles of hemolysin and other toxins in enteropathy caused by alpha-hemolytic Escherichia coli linked to human diarrhea.
Infect. Immun.
66:2040-2051 |
| 8. |
Falbo, V.,
T. Pace,
L. Picci,
E. Pizzi, and A. Caprioli.
1993.
Isolation and nucleotide sequence of the gene encoding cytotoxic necrotizing factor 1 of Escherichia coli.
Infect. Immun.
61:4909-4914 |
| 9. | Falzano, L., C. Fiorentini, G. Donelli, E. Michel, C. Kocks, P. Cossart, L. Cabanié, E. Oswald, and P. Boquet. 1993. Induction of phagocytic behavior in human epithelial cells by Escherichia coli cytotoxic necrotizing factor type 1. Mol. Microbiol. 9:1247-1254[Medline]. |
| 10. | Fiorentini, C., G. Arancia, A. Caprioli, V. Falbo, F. M. Ruggeri, and G. Donelli. 1988. Cytoskeletal changes induced in HEp-2 cells by the cytotoxic necrotizing factor of Escherichia coli. Toxicon 26:1047-1056[Medline]. |
| 11. | Fiorentini, C., A. Fabbri, P. Matarrese, L. Falzano, P. Boquet, and W. Malorni. 1997. Hinderance of apoptosis and phagocytic behaviour induced by Escherichia coli cytotoxic necrotizing factor 1: two related activities in epithelial cells. Biochem. Biophys. Res. Commun. 241:341-346[CrossRef][Medline]. |
| 12. | Flatau, G., E. Lemichez, M. Gauthier, P. Chardin, S. Paris, C. Fiorentini, and P. Boquet. 1997. Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. Nature 387:729-733[CrossRef][Medline]. |
| 13. |
Fournout, S.,
C. M. Dozois,
M. Odin,
C. Desautels,
S. Pérès,
F. Hérault,
F. Daigle,
S. Segafredo,
J. Laffitte,
E. Oswald,
J. M. Fairbrother, and I. P. Oswald.
2000.
Lack of a role of cytotoxic necrotizing factor 1 toxin from Escherichia coli in bacterial pathogenicity and host cytokine response in infected germfree piglets.
Infect. Immun.
68:839-847 |
| 14. |
Gerhard, R.,
G. Schmidt,
F. Hofmann, and K. Aktories.
1998.
Activation of Rho GTPases by Escherichia coli cytotoxic necrotizing factor 1 increases intestinal permeability in Caco-2 cells.
Infect. Immun.
66:5125-5131 |
| 15. |
Hagberg, L.,
I. Engberg,
R. Freter,
J. Lam,
S. Olling, and C. Svanborg Eden.
1983.
Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin.
Infect. Immun.
40:273-283 |
| 16. |
Hamilton, C. M.,
M. Aldea,
B. K. Washburn,
P. Babitzke, and S. R. Kushner.
1989.
New method for generating deletions and gene replacements in Escherichia coli.
J. Bacteriol.
171:4617-4622 |
| 17. |
Hedlund, M.,
M. Svensson,
A. Nilsson,
R.-D. Duan, and C. Svanborg.
1996.
Role of the ceramide-signaling pathway in cytokine responses to P-fimbriated Escherichia coli.
J. Exp. Med.
183:1037-1044 |
| 18. |
Hofman, P.,
G. Flatau,
E. Selva,
M. Gauthier,
G. Le Negrate,
C. Fiorentini,
B. Rossi, and P. Boquet.
1998.
Escherichia coli cytotoxic necrotizing factor 1 effaces microvilli and decreases transmigration of polymorphonuclear leukocytes in intestinal T84 epithelial cell monolayers.
Infect. Immun.
66:2494-2500 |
| 19. |
Hofman, P.,
G. Le Negrate,
B. Mograbi,
V. Hofman,
P. Brest,
A. Alliana-Schmid,
G. Flatau,
P. Boquet, and B. Rossi.
2000.
Escherichia coli cytotoxic necrotizing factor-1 (CNF-1) increases the adherence to epithelia and the oxidative burst of human polymorphonuclear leukocytes but decreases bacterial phagocytosis.
J. Leukoc. Biol.
68:522-528 |
| 20. |
Hooton, T. M.,
D. Scholes,
J. P. Hughes,
C. Winter,
P. L. Roberts,
A. E. Stapleton,
A. Stergachis, and W. E. Stamm.
1996.
A prospective study of risk factors for symptomatic urinary tract infection in young women.
N. Engl. J. Med.
335:468-474 |
| 21. | Hooton, T. M., and W. E. Stamm. 1997. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. N. Am. 11:551-582[CrossRef][Medline]. |
| 22. |
Hopkins, W. J.,
A. Gendron-Fitzpatrick,
E. Balish, and D. T. Uehling.
1998.
Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains.
Infect. Immun.
66:2798-2802 |
| 23. |
Hull, R. A.,
R. E. Gill,
P. Hsu,
B. H. Minshew, and S. Falkow.
1981.
Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli isolate.
Infect. Immun.
33:933-938 |
| 24. |
Island, D. M.,
X. Cui, and J. W. Warren.
1999.
Effect of Escherichia coli cytotoxic necrotizing factor 1 on repair of human bladder cell monolayers in vitro.
Infect. Immun.
67:3657-3661 |
| 25. | Jacobson, S. H., Y. Lu, and A. Brauner. 1998. Soluble interleukin-6 receptor, interleukin-10 and granulocyte colony-stimulating factor in acute pyelonephritis: relationship to markers of bacterial virulence and renal function. Nephron 80:401-407[CrossRef][Medline]. |
| 26. | Johnson, D. E., C. Drachenberg, C. V. Lockatell, M. D. Island, J. W. Warren, and M. S. Donnenberg. 2000. The role of cytotoxic necrotizing factor-1 in colonization and tissue injury in a murine model of urinary tract infection. FEMS Immunol. Lett. 28:37-41. |
| 27. |
Johnson, D. E.,
C. V. Lockatell,
R. G. Russell,
J. R. Hebel,
M. D. Island,
A. Stapleton,
W. E. Stamm, and J. W. Warren.
1998.
Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.
Infect. Immun.
66:3059-3065 |
| 28. |
Johnson, D. E.,
R. G. Russell,
C. V. Lockatell,
J. C. Zulty, and J. W. Warren.
1993.
Urethral obstruction of 6 hours or less causes bacteriuria, bacteremia, and pyelonephritis in mice challenged with "nonuropathogenic" Escherichia coli.
Infect. Immun.
61:3422-3428 |
| 29. |
Johnson, J. R.
1991.
Virulence factors in Escherichia coli urinary tract infection.
Clin. Microbiol. Rev.
4:80-128 |
| 30. |
Lerm, M.,
G. Schmidt,
U.-M. Goehring,
J. Schirmer, and K. Aktories.
1999.
Identification of the region of Rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1).
J. Biol. Chem.
274:28999-29004 |
| 31. | McKee, M. L., A. R. Melton-Celsa, R. A. Moxley, D. H. Francis, and A. D. O'Brien. 1995. Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells. Infect. Immun. 63:3739-3744[Abstract]. |
| 32. | Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 33. | Miller, T. E., and E. Creaghe. 1976. Bacterial interference as a factor in renal infection. J. Lab. Clin. Med. 87:792-803[Medline]. |
| 34. |
Mills, M.,
K. C. Meysick, and A. D. O'Brien.
2000.
Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.
Infect. Immun.
68:5869-5880 |
| 35. | Mitsumori, K., A. Terai, S. Yamamoto, S. Ishitoya, and O. Yoshida. 1999. Virulence characteristics of Escherichia coli in acute bacterial prostatitis. J. Infect. Dis. 180:1378-1381[CrossRef][Medline]. |
| 36. |
Mobley, H. L.,
D. M. Green,
A. L. Trifillis,
D. E. Johnson,
G. R. Chippendale,
C. V. Lockatell,
B. D. Jones, and J. W. Warren.
1990.
Pyelonephritic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains.
Infect. Immun.
58:1281-1289 |
| 37. | Mobley, H. L., K. G. Jarvis, J. P. Elwood, D. I. Whittle, C. V. Lockatell, R. G. Russell, D. E. Johnson, M. S. Donnenberg, and J. W. Warren. 1993. Isogenic P-fimbrial deletion mutants of pyelonephritic Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain. Mol. Microbiol. 10:143-155[Medline]. |
| 38. | National Institutes of Health. 1985. Guide for the care and use of laboratory animals. Publication no. 85-23. National Institutes of Health, Bethesda, Md. |
| 39. | Neu, H. C. 1992. Urinary tract infections. Am. J. Med. 92:63S-70S[CrossRef][Medline]. |
| 40. | Ruggeri, F. M., C. Fiorentini, A. Caprioli, G. Arancia, V. Falbo, and G. Donelli. 1986. HEp-2 cell multinucleation induced by an E. coli cytotoxic factor. IRCS Med. Sci. 14:833-834. |
| 41. | Russo, T., J. E. Guenther, S. Wenderoth, and M. M. Frank. 1993. Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol. Microbiol. 9:357-364[CrossRef][Medline]. |
| 42. | Schmidt, G., P. Sehr, M. Wilm, J. Selzer, M. Mann, and K. Aktories. 1997. Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature 387:725-729[CrossRef][Medline]. |
| 43. | Swenson, D. L., N. O. Bukanov, D. E. Berg, and R. A. Welch. 1996. Two pathogenicity islands in uropathogenic Escherichia coli J96: cosmid cloning and sample sequencing. Infect. Immun. 64:3736-3743[Abstract]. |
| 44. | Warren, J. W. 1996. Clinical presentations and epidemiology of urinary tract infections, p. 3-27. In H. L. T. Mobley, and J. W. Warren (ed.), Urinary tract infections: molecular pathogenesis and clinical management. ASM Press, Washington, D.C. |
| 45. | Yamamoto, S., T. Tsukamoto, A. Terai, H. Kurazono, Y. Takeda, and O. Yoshida. 1995. Distribution of virulence factors in Escherichia coli isolated from urine of cystitis patients. Microbiol. Immunol. 39:401-404[Medline]. |
This article has been cited by other articles: